STAT

Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer

New research raises the possibility that liquid biopsies could be used to spot cancer in a totally different way: by hunting for the DNA of bacteria and viruses released from…
A new study found that Fusobacterium, pictured above, was significantly more abundant in all gastrointestinal cancers versus all other major cancer types in the human body.

The many companies developing liquid biopsies to try to detect cancer early have so far largely mined the blood in search of things like mutations and epigenetic changes in human DNA shed by tumor cells.

Now, new research raises the possibility that liquid biopsies could be used to spot cancer in a totally different way: by hunting for the DNA of bacteria and viruses released from tumors into the bloodstream. It’s a hypothesis that, if validated with more study, could usher in an entirely new class of diagnostics for cancer.

In a , a team led by researchers at the University of California, San Diego, reported that they

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks